Talkitt, an Israeli-made technology from VoiceITT that translates unintelligible pronunciation from any language into understandable speech won first prize in the fourth annual international Medica medical app competition in Dusseldorf on November 17, 2015.
Medica is the world’s largest medical trade fair, attracting nearly 5, 000 exhibitors from 70 nations.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at [email protected].
Thank you.
The grand prize package included the newest Apple iPad and one exhibition visitor pass for the Mobile World Congress in Barcelona in February 2016.
VoiceITT’s revolutionary Talkitt app to enable communication voice-translation technology for the disabled for people with ALS, autism, Parkinson’s disease and other speech-affecting disabilities also won the audience favorite award at a startup showcase at the Wall Street Journal’s live global technology conference a year ago. Talkitt’s numerous other accolades include the Verizon Powerful Answers Award in 2014.
Medica 2015 judges focused on the best medical apps for use in the daily routine of a doctor or in the hospital.
Their third-place pick was Israel-based MobileODT (formerly Mobile OCT), which developed CervDx, an app-based visual assessment system for cervical cancer screenings anywhere Internet is available.
Other Israeli top-10 finalists chosen to give live pitches at the Medica competition this year were iFeel Labs Match3, a game using a biosensor to help asthma and COPD patients learn how to breathe effectively and improve pulmonary function; and Doctome by MedTrix, an innovative telemedicine platform that enables 24/7 online medical services using video calls and chat anywhere around the globe, provided by doctors speaking the patient’s language.
